India, Jan. 10 -- Pfizer Inc. (PFE) announced positive results from Cohort 3 of the pivotal BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation.
Pfizer Inc. (PFE) announced positive results from Cohort 3 of the pivotal BREAKWATER trial, evaluating BRAFTOVI (encorafenib) in combination with cetuximab (ERBITUX) and FOLFIRI (fluorouracil, leucovorin, and irinotecan) in patients with previously untreated metastatic colorectal cancer (mCRC) harboring the BRAF V600E mutation.
The analysis revealed that the BRAFTOVI regimen with cetuximab and FOL...